We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

232 hedge funds and large institutions have $4.15B invested in Loxo Oncology, Inc in 2018 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 77 increasing their positions, 85 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more call options, than puts

Call options by funds: $21.9M | Put options by funds: $12.3M

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

16% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 31

2% more funds holding

Funds holding: 228232 (+4)

9% less repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 85

19% less capital invested

Capital invested by funds: $5.13B → $4.15B (-$971M)

Holders
232
Holders Change
+4
Holders Change %
+1.75%
% of All Funds
5.17%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.16%
New
36
Increased
77
Reduced
85
Closed
31
Calls
$21.9M
Puts
$12.3M
Net Calls
+$9.55M
Net Calls Change
-$5.66M
Name Holding Trade Value Shares
Change
Change in
Stake
NIP
76
Nicholas Investment Partners
California
$4.47M -$54K -356 -1%
FCM
77
Frontier Capital Management
Massachusetts
$4.44M -$3.01M -19,814 -38%
AQR Capital Management
78
AQR Capital Management
Connecticut
$4.41M +$881K +5,802 +23%
Marshall Wace
79
Marshall Wace
United Kingdom
$4.24M +$4.59M +30,263 New
State of Wisconsin Investment Board
80
State of Wisconsin Investment Board
Wisconsin
$3.87M +$45.5K +300 +1%
GH
81
GAM Holding
Switzerland
$3.8M -$469K -3,089 -10%
ACM
82
Aquilo Capital Management
California
$3.47M -$12.8M -84,562 -77%
TCM
83
Tekla Capital Management
Massachusetts
$3.44M
GC
84
Guggenheim Capital
Illinois
$3.42M -$376K -2,480 -9%
Man Group
85
Man Group
United Kingdom
$3.41M -$433K -2,851 -10%
Capital Fund Management (CFM)
86
Capital Fund Management (CFM)
France
$3.17M -$1.9M -12,490 -36%
PAM
87
Panagora Asset Management
Massachusetts
$3.12M
MOACM
88
Mutual of America Capital Management
New York
$3.12M
PVAM
89
Pacific View Asset Management
California
$3.05M +$2.48M +16,321 +299%
ACM
90
Atika Capital Management
New York
$2.94M +$607K +4,000 +24%
MAP
91
Moody Aldrich Partners
Massachusetts
$2.85M +$40.5K +267 +1%
AIMCA
92
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$2.77M +$3.01M +19,800 New
Manulife (Manufacturers Life Insurance)
93
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2.57M +$134K +886 +5%
PI
94
Putnam Investments
Massachusetts
$2.5M +$509K +3,350 +23%
AIG
95
American International Group
New York
$2.48M -$20.8K -137 -0.8%
QI
96
QS Investors
New York
$2.47M
PPA
97
Parametric Portfolio Associates
Washington
$2.38M -$715K -4,711 -22%
EAM
98
Erste Asset Management
Austria
$2.33M +$2.63M +17,300 New
SEI Investments
99
SEI Investments
Pennsylvania
$2.26M -$10.3K -68 -0.5%
RJA
100
Raymond James & Associates
Florida
$2.19M +$1.55M +10,218 +189%

LOXO Hedge Fund Activity: Q4 2018 in Review

232 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q4 2018, worth a combined $4.15B — down 19% from $5.13B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new LOXO positions and 31 closed out — a net gain of 5 holders — while 77 added to existing stakes and 85 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $72.3M. The largest seller was OrbiMed, exiting entirely with an estimated $56.4M sold.

  • 232 institutional investors held Loxo Oncology, Inc (LOXO) as of Q4 2018, up from 228 in Q3 2018.
  • Funds reported $4.15B of Loxo Oncology, Inc stock for Q4 2018, down 19% quarter-over-quarter.
  • 36 funds opened new Loxo Oncology, Inc positions in Q4 2018 and 31 closed out, a net change of +5 holders.
  • The largest Loxo Oncology, Inc buyer in Q4 2018 was Point72 Asset Management, an estimated $72.3M added.
  • The largest Loxo Oncology, Inc seller in Q4 2018 was OrbiMed, an estimated $56.4M sold.

Based on aggregated 13F filings for Q4 2018.